切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2023, Vol. 11 ›› Issue (01) : 56 -61. doi: 10.3877/cma.j.issn.2095-655X.2023.01.011

临床研究

IgG4相关性疾病的临床诊断学特征
王丽军1, 韩孟汝1, 董春霞1, 杨林花1, 王梅芳1,()   
  1. 1. 030001 太原,山西医科大学第二医院血液科
  • 收稿日期:2022-10-30 出版日期:2023-02-26
  • 通信作者: 王梅芳
  • 基金资助:
    山西省教育厅研究生教育改革项目(2017JG40); 山西卫生计划委员会住院医师规范化培训科研项目(2017064)

Clinical diagnostic features of IgG4-related diseases

Lijun Wang1, Mengru Han1, Chunxia Dong1, Linhua Yang1, Meifang Wang1,()   

  1. 1. Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2022-10-30 Published:2023-02-26
  • Corresponding author: Meifang Wang
引用本文:

王丽军, 韩孟汝, 董春霞, 杨林花, 王梅芳. IgG4相关性疾病的临床诊断学特征[J/OL]. 中华诊断学电子杂志, 2023, 11(01): 56-61.

Lijun Wang, Mengru Han, Chunxia Dong, Linhua Yang, Meifang Wang. Clinical diagnostic features of IgG4-related diseases[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(01): 56-61.

目的

探讨IgG4相关性疾病(IgG4-RD)的诊断学特征。

方法

回顾性分析2014年4月至2020年9月在山西医科大学第二医院就诊的IgG4-RD患者的临床资料,将患者分为确诊病例组和可能确诊病例组(包括可能诊断和可疑诊断),观察两组患者在年龄、性别、病程持续时间、IgG4水平等的差异。Spearman相关性分析累及器官个数与病程持续时间的关系。Kruskal-Wallis H检验分析累及器官个数与IgG4水平的关系。

结果

68例IgG4-RD患者中,男女性别比为1.27∶1,中位年龄59(50,65)岁。主要首发临床表现为下颌肿物29例(42.65%),眼睑肿物11例(16.18%),其他临床表现为腹痛、腹胀、黄疸、肩腰背部疼痛、鼻塞、流涕、视物模糊、咽部异物感、心绞痛、皮疹、气短、尿崩症等。最常见受累器官主要为淋巴结37例(54.41%)、颌下腺29例(42.65%)、胰腺胆道15例(22.06%)、泪腺11例(16.18%)、腮腺8例(11.76%)、腹膜后纤维化7例(10.29%)。血清IgG4水平>1 350 mg/L 47例(69.12%)。超声局部探查或CT/MRI影像学可表现为1个或多个器官局限或弥漫性肿大、结节、壁增厚、受累器官旁软组织影、淋巴结增大等。有55例进行组织病理学检查,获取病理标本部位常见的为颌下腺(29/55,52.73%)、眼眶肿物(11/55,20.00%)、胰腺(8/55,14.55%)。病理表现为淋巴细胞、浆细胞浸润,部分有嗜酸性粒细胞浸润及纤维组织增生。免疫组化染色IgG4阳性细胞20~50个/HPF,IgG4+/IgG+ 20%~50%。多数患者采用激素或联合免疫抑制剂治疗后病情转归,2例高龄患者因合并梗阻性肾病、慢性肾功能衰竭死亡。34例确诊患者中,Spearman相关性分析显示病程长短与累及器官个数显著相关(r=0.33,P=0.005);Kruskal-Wallis H检验结果显示受累器官个数与IgG4水平比较,差异无统计学意义(H=4.73,P=0.192)。

结论

IgG4-RD临床表现高度异质性,IgG4水平尚不能作为判断疾病严重程度的指标。

Objective

To explore the diagnostic features of IgG4-related diseases (IgG4-RD).

Methods

The clinical data of IgG4-RD patients treated in the Second Hospital of Shanxi Medical University from April 2014 to September 2020 were retrospectively analyzed, and the patients were divided into a confirmed case group and a probable confirmed case group (including probable and suspected diagnosis). The differences in age, gender, duration of disease and IgG4 levels between the 2 groups were observed. The relationship between the number of organs involved and the duration of the disease was analyzed by the Spearman correlation, and the relationship between the number of organs involved and the level of IgG4 was analyzed by the Kruskal-Wallis H test.

Results

Among the 68 patients with IgG4-RD, the male to female sex ratio was 1.27∶1, and the median age was 59(50, 65) years. In 29 cases (42.65%) and 11 cases (16.18%), mandibular and eyelid enlargement were the first clinical manifestations, respectively. Other clinical manifestations included abdominal pain, abdominal distention, jaundice, shoulder and back pain, nasal congestion, runny nose, blurred vision, pharyngeal foreign body sensation, angina, rash, shortness of breath, uroparesis were also observed, the most commonly affected organs in 37 cases (54.41%), followed by the submandibular gland in 29 cases (42.65%), pancreaticobiliary ducts in 15 cases (22.06%), lacrimal glands in 11 cases (16.18%), parotid glands in 8 cases (11.76%), and retroperitoneal fibrosis in 7 cases (10.29%). Serum IgG4 levels in 47 cases (69.12%) were more than 1 350 mg/L. Local ultrasound exploration or CT/MRI imaging may showed one or more organs with localized or diffuse enlargement, nodules, wall thickening, soft tissue shadowing next to the involved organ, and enlarged lymph nodes. At the location where 55 cases′ pathological specimens were collected, submandibular glands (29/55, 52.73%), orbital masses (11/55, 20.00%), and pancreas (8/55, 14.55%) were frequent. Pathological manifestations included lymphocytic and plasma cell infiltration, as well as eosinophilic infiltration and fibrous tissue hyperplasia in some cases. Immunohistochemical staining showed that there were 20-50/HPF, IgG4+ /IgG+ 20%-50%. Most patients improved after being treated with hormones or combined immunosuppressants. Two elderly patients died due to obstructive nephropathy and chronic renal failure. Among the 34 confirmed patients, Spearman correlation analysis revealed a significant correlation between the duration of the disease and the number of organs involved (r=0.33, P=0.005). The Kruskal-Wallis H test showed no statistically significant difference between the numbers of organs involved and IgG4 levels (H=4.73, P=0.192).

Conclusions

The clinical manifestations of IgG4-RD are highly heterogeneous, and the level of IgG4 cannot be used to assess the severity of the disease.

表1 68例IgG4相关性疾病患者临床资料
表2 两组IgG4相关性疾病患者临床资料比较
表3 IgG4相关性疾病患者IgG4水平与累及器官个数的关系
[1]
Perugino CA, Stone JH.IgG4-related disease:an update on pathophysiology and implications for clinical care[J].Nat Rev Rheumatol202016(12):702-714.DOI:10.1038/s41584-020-0500-7.
[2]
Umehara H, Okazaki K, Masaki Y,et al.Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD),2011[J].Mod Rheumatol201222(1):21-30.DOI:10.1007/s10165-011-0571-z.
[3]
Kamisawa T, Zen Y, Pillai S,et al.IgG4-related disease[J].Lancet2015385(9976):1460-1471.DOI:10.1016/S0140-6736(14)60720-0.
[4]
张盼盼,赵继志,王木,等.IgG-4相关性疾病346例临床特征分析[J].中华内科杂志201756(9):644-649.DOI:10.3760/cma.j.issn.0578-1426.2017.09.005.
[5]
Okazaki K, Umehara H.Current Concept of IgG4-related disease[J].Curr Top Microbiol Immunol2017(401):1-17.DOI: 10.1007/82_2016_47.
[6]
Wallace ZS, Deshpande V, Mattoo H,et al.IgG4-related disease:clinical and laboratory features in one hundred twenty-five patients[J].Arthritis Rheumatol201567(9):2466-2475.DOI: 10.1002/art.39205.
[7]
张勇,周合冰.48例IgG4相关性疾病患者的临床特征及治疗情况[J].中华全科医师杂志201918(11):1088-1091.DOI: 10.3760/cma.j.issn.1671-7368.2019.11.015.
[8]
Skopouli FN, Panayotopoulos P, Moutsopoulos HM.IgG4-related nodular lung lesion[J].Arthritis Rheumatol201769(2):438.DOI: 10.1002/art.39994.
[9]
Kaur K, Kakkar A, Manchanda S,et al.Sinonasal IgG4-related disease:a rare and emerging entity broadening the differential diagnosis in the sinonasal universe[J].Eur Arch Otorhinolaryngol2021278(8):2883-2890.DOI: 10.1007/s00405-020-06564-w.
[10]
张碧君,章殷希,丁美萍.IgG4相关性肥厚性硬脑膜炎的研究进展[J].中华医学杂志201696(47):3851-3854.DOI: 10.3760/cma.j.issn.0376-2491.2016.47.020.
[11]
Deshpande V, Zen Y, Chan JK,et al.Consensus statement on the pathology of IgG4-related disease[J].Mod Pathol201225(9):1181-1192.DOI: 10.1038/modpathol.2012.72.
[12]
Arora K, Rivera M, Ting DT,et al.The histological diagnosis of IgG4-related disease on small biopsies:challenges and pitfalls[J].Histopathology201974(5):688-698.DOI: 10.1111/his.13787.
[13]
Wallace ZS, Naden RP, Chari S,et al.The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J].Ann Rheum Dis202079(1):77-87.DOI:10.1136/annrheumdis-2019-216561.
[14]
李道胜,班媛媛.IgG4相关性疾病的临床诊断学特征[J/CD].中华诊断学电子杂志20186(4):264-267.DOI:10.3877/cma.j.issn.2095-655X.2018.04.011.
[15]
张丽娟,纪宗斐,姜林娣.抗中性粒细胞胞质抗体相关性血管炎重叠IgG4相关性疾病四例并文献复习[J].中华风湿病学杂志202024(4):268-272,C2.DOI: 10.3760/cma.j.cn141217-20191109-00367.
[16]
Löhr JM, Vujasinovic M, Rosendahl J,et al.IgG4-related diseases of the digestive tract[J].Nat Rev Gastroenterol Hepatol202219(3):185-197.DOI:10.1038/s41575-021-00529-y.
[17]
Omar D, Chen Y, Cong Y,et al.Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis[J].Rheumatology (Oxford)202059(4):718-726.DOI: 10.1093/rheumatology/kez380.
[18]
Lanzillotta M, Fernàndez-Codina A, Culver E,et al.Emerging therapy options for IgG4-related disease[J].Expert Rev Clin Immunol202117(5):471-483.DOI: 10.1080/1744666X.2021.1902310.
[19]
Kamisawa T, Funata N, Hayashi Y,et al.A new clinicopathological entity of IgG4-related autoimmune disease[J].J Gastroenterol200338(10):982-984.DOI: 10.1007/s00535-003-1175-y.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[3] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[10] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[12] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要